Autolus Therapeutics (NASDAQ:AUTL) Trading Down 0.7% – Here’s Why

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) was down 0.7% on Tuesday . The stock traded as low as $1.41 and last traded at $1.45. 527,206 shares traded hands during trading, a decline of 52% from the average daily volume of 1,098,452 shares. The stock had previously closed at $1.46.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AUTL. Wall Street Zen upgraded Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 9th. HC Wainwright raised their target price on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Weiss Ratings raised shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Finally, Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $8.75.

Autolus Therapeutics Stock Up 4.8%

The stock has a market cap of $407.22 million, a P/E ratio of -1.40 and a beta of 2.04. The business has a 50 day moving average price of $1.57 and a two-hundred day moving average price of $1.53.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The firm had revenue of $26.22 million during the quarter, compared to analysts’ expectations of $26.27 million. On average, research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.95 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AUTL. GAMMA Investing LLC boosted its position in shares of Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after acquiring an additional 8,309 shares during the last quarter. Independent Advisor Alliance bought a new stake in Autolus Therapeutics in the 4th quarter valued at $28,000. Marex Group plc purchased a new stake in Autolus Therapeutics in the 2nd quarter worth $28,000. Waverly Advisors LLC purchased a new stake in Autolus Therapeutics in the 1st quarter worth $37,000. Finally, SmartHarvest Portfolios LLC bought a new position in shares of Autolus Therapeutics during the 4th quarter valued at about $43,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.